Executive Summary: Key Market Implications
In a pivotal move for China’s equity markets, the National Financial Regulatory Administration (金融监管总局) has introduced regulatory adjustments designed to channel more long-term capital into A-shares. This article breaks down the critical changes and their far-reaching implications for investors and the market.
- The regulator has significantly lowered risk factors for insurance companies’ long-term holdings in key indices like the CSI 300 (沪深300指数) and the STAR Market (科创板), directly reducing capital charges and boosting solvency ratios.
- By incentivizing ‘patient capital’ with holding period-based discounts, the policy aims to stabilize markets, support technological innovation, and align with national strategic goals.
- Adjustments also extend to export credit insurance, lowering capital requirements to bolster foreign trade and overseas investment, reflecting a broader economic support framework.
- Industry experts hail this as a crucial step to address insurers’ capital constraints in a low-rate environment, potentially unlocking substantial new equity investment.
- This regulatory easing builds on previous measures and is expected to enhance the role of insurance funds as a stabilizing, long-term force in China’s capital markets.
A Strategic Inflection Point for A-Share Liquidity
China’s A-share market stands at the cusp of a significant liquidity infusion, driven by a nuanced regulatory shift aimed at the insurance sector. On December 5, the National Financial Regulatory Administration (金融监管总局) issued the ‘Notice on Adjusting Risk Factors for Insurance Companies’ Related Businesses’ (关于调整保险公司相关业务风险因子的通知), a document that meticulously recalibrates the capital costs associated with equity investments. This move is not merely a technical adjustment; it is a deliberate strategy to cultivate patient capital within the domestic financial system. By making it more capital-efficient for insurers to hold stocks for extended periods, the regulator seeks to transform insurance funds into a bedrock of stability for the equity market. This initiative directly responds to the longstanding call from institutional investors for policies that reward long-term conviction over short-term speculation, potentially altering the investment horizon for one of China’s most significant pools of institutional capital.
Decoding the Core Mechanism: Risk Factor Reductions
The heart of the notice lies in its targeted reductions of ‘risk factors’—coefficients used to calculate the minimum capital insurers must hold against different assets. Lower factors mean less capital is tied up, freeing up balance sheet capacity for further investment. The adjustments are precisely tiered based on the type of equity and, critically, the duration of holding.
- For holdings in CSI 300 Index (沪深300指数) constituents and CSI Dividend Low Volatility 100 Index (中证红利低波动100指数) constituents held for over three years, the risk factor is reduced from 0.30 to 0.27.
- For holdings in STAR Market (科创板) listed ordinary shares held for over two years, the risk factor drops from 0.40 to 0.36.
- The holding period is calculated using a weighted-average method over the past six years for main board stocks and four years for STAR Market stocks, applying a ‘first-in, first-out’ principle.
This structured approach ensures that the benefits accrue specifically to insurers demonstrating a commitment to long-term investment, thereby embedding the concept of patient capital into regulatory capital standards.
The Regulatory Philosophy: Cultivating Long-Term Stewardship
The December notice is rooted in a clear regulatory philosophy articulated by senior officials. The relevant department head of the National Financial Regulatory Administration (金融监管总局) stated that the adjustments are essential ‘to effectively prevent risks, guide insurance companies to improve long-term investment management capabilities, strengthen asset-liability matching management, better leverage the role of insurance funds as patient capital, and effectively serve the real economy.’ This statement underscores a dual objective: enhancing the financial resilience of insurers while directing their substantial capital toward productive, long-term economic ends. The focus on patient capital is a deliberate counter to market volatility, aiming to insulate key segments of the A-share market from the whims of short-term traders. By lowering the cost of carrying long-term equity positions, the regulator is effectively subsidizing stability and encouraging insurers to act as foundational investors in China’s corporate landscape.
Expert Endorsement and Industry Perspective
Industry leaders have welcomed these measures as a pragmatic solution to capital constraints. Zhou Jin (周瑾), Insurance Consulting Managing Partner at Tianzh International (天职国际), noted that on top of existing measures like raising investment ratio limits and extending assessment cycles, this move provides a direct capital incentive. ‘For the insurance industry, which is generally under capital pressure, this notice will reduce the capital occupation of existing holdings and improve the solvency adequacy ratio level, thereby freeing up capital space and further enhancing the enthusiasm for insurance funds to enter the market and hold for the long term,’ Zhou explained. This sentiment is echoed by Yu Yong (于泳), Party Committee Secretary and President of China Life Asset Management (国寿资产), who had previously advocated for refining risk factor classifications based on investment领域 (field) and holding期限 (period). The regulatory change aligns perfectly with such recommendations, demonstrating a responsive approach to market feedback.
Historical Context and Cumulative Impact
The latest adjustments are part of a sequenced regulatory easing campaign aimed at mobilizing insurance capital. This focus on patient capital is not new. As far back as May 7 of this year, Li Yunze (李云泽), head of the National Financial Regulatory Administration (金融监管总局), explicitly called for leveraging insurance funds as ‘patient capital, long-term capital’ and increasing market entry to stabilize prices. The current notice operationalizes that vision. It builds directly upon a prior adjustment in September 2023, when the regulator first optimized solvency监管标准 (supervision standards), lowering risk factors for CSI 300 investments from 0.35 to 0.30 and for STAR Market stocks from 0.45 to 0.40. Market institutions estimated that the 2023 change alone could lift the industry’s average solvency adequacy ratio by approximately 18.6 percentage points. The December 2024 tweaks, which further reduce factors for long-duration holdings, represent a deepening of this policy trajectory. They acknowledge that in a persistent low-interest-rate environment, insurers have a latent demand for higher equity allocation, but are often hamstrung by solvency calculations. By systematically addressing this bottleneck, the regulator is incrementally unlocking hundreds of billions in potential investment capacity.
Quantifying the Solvency Boost
The mechanics of the solvency boost are straightforward. A lower risk factor directly decreases the ‘required capital’ for a given asset portfolio. For an insurer with a large, long-term holding in CSI 300 stocks, the reduction from 0.30 to 0.27 represents a 10% decrease in the capital charge for that portion of its book. This freed-up capital can either improve the firm’s regulatory solvency ratio—a key health metric—or be redeployed into new investments without breaching capital limits. The cumulative effect across the entire insurance industry, which manages over RMB 20 trillion in assets, could be substantial, providing a much-needed buffer and encouraging incremental flows into the A-share market.
Broadening the Horizon: Support for Tech and Trade
The regulatory shift extends its support beyond broad market indices to specifically champion strategic economic sectors. The preferential treatment for STAR Market (科创板) stocks is a clear directive to funnel patient capital into China’s technology and innovation frontier. The regulator’s department head explicitly stated that the differentiated risk factor setup aims to ‘cultivate and expand patient capital and support科技创新 (technological innovation).’ This aligns with national priorities to achieve technological self-reliance and advance up the value chain. Furthermore, the notice also adjusts factors for export credit insurance业务 (business), lowering the premium risk factor from 0.467 to 0.42 and the reserve risk factor from 0.605 to 0.545 for both general insurers and the China Export & Credit Insurance Corporation (中国出口信用保险公司). Research analysts indicate this similarly reduces capital requirements for overseas investment insurance. The regulator clarified this will ‘guide insurance companies to increase support for foreign trade enterprises and effectively serve the national strategy.’ Thus, the policy framework deftly links domestic market stability with international competitiveness, using insurance capital as a tool for broad economic stewardship.
The STAR Market as a Beneficiary
The STAR Market, often compared to Nasdaq, houses many high-growth but capital-intensive technology firms. By making it cheaper for insurers to hold these stocks for the long term, the policy not only provides these companies with more stable shareholder bases but also signals regulatory confidence in their growth trajectory. This can lower the cost of equity for innovators and foster a more resilient ecosystem for patient capital in China’s tech sector.
Implementation and Forward-Looking Guidance
The National Financial Regulatory Administration (金融监管总局) has indicated that the next step involves guiding insurance companies to diligently implement the notice’s requirements. The focus will be on推动 (promoting) insurers to enhance their long-term capital investment management capabilities and strengthen偿付能力管理 (solvency management) to ensure data authenticity, accuracy, and completeness. For market participants, this translates into a clear signal: the regulatory environment is increasingly favorable for long-term, value-oriented investment strategies in A-shares. Insurers are now incentivized to develop or bolster their in-house equity research and portfolio management teams focused on multi-year horizons. Asset managers and analysts should closely monitor insurance company filings in the coming quarters for signs of increased positioning in eligible index constituents and STAR Market listings. The sustained flow of this patient capital could begin to materially impact valuation models, placing a premium on stability, dividend yield, and strategic alignment with national interests.
Call to Action for Global Investors
For sophisticated international investors, this regulatory evolution underscores the importance of understanding the unique drivers of Chinese market liquidity. The deliberate cultivation of domestic patient capital represents a structural tailwind for A-shares, particularly in sectors deemed strategically important. Investors should factor this into their asset allocation decisions, recognizing that policies are actively working to reduce volatility and enhance the appeal of long-term holdings. Engaging with research that tracks insurance fund flow data and solvency trends will become increasingly crucial. Moreover, this move highlights the Chinese regulator’s commitment to using nuanced financial监管工具 (supervision tools) to achieve macro-stability, a theme likely to persist and influence other asset classes. As patient capital becomes a more entrenched feature of the landscape, aligning investment theses with this long-term orientation will be key to capturing the evolving opportunities in China’s equity markets.